Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le dimanche 05.04.2020 à 10:00 AM CEST
Paramétrages

Paramétrages

1. WO2005000334 - COMPOSES D'AMPHETAMINE RESISTANT AUX ABUS

Numéro de publication WO/2005/000334
Date de publication 06.01.2005
N° de la demande internationale PCT/US2004/017204
Date du dépôt international 01.06.2004
CIB
A61K 38/00 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
CPC
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 47/542
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
542Carboxylic acids, e.g. a fatty acid or an amino acid
C07C 237/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
02having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
04the carbon skeleton being acyclic and saturated
06having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Y02A 50/415
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
408the vector-borne disease being caused by a protozoa
413of the genus Trypanosoma
415the protozoa being Trypanosoma brucei gambiense or Trypanosoma brucei rhodesiense, i.e. Human African trypanosomiasis or sleeping sickness
Y10S 436/901
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
436Chemistry: analytical and immunological testing
901Drugs of abuse, e.g. narcotics, amphetamine
Y10T 436/173845
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
436Chemistry: analytical and immunological testing
17Nitrogen containing
173845Amine and quaternary ammonium
Déposants
  • NEW RIVER PHARMACEUTICALS, INC. [US/US]; The Governor Tyler 1881 Grove Avenue Radford, VA 24141, US (AllExceptUS)
  • MICKLE, Travis [US/US]; US (UsOnly)
  • KRISHNAN, Suma [US/US]; US (UsOnly)
  • BISHOP, Barney [US/US]; US (UsOnly)
  • LAUDERBACK, Christopher [US/US]; US (UsOnly)
  • MONCRIEF, James, Scott [US/US]; US (UsOnly)
  • OBERLENDER, Rob [US/US]; US (UsOnly)
Inventeurs
  • MICKLE, Travis; US
  • KRISHNAN, Suma; US
  • BISHOP, Barney; US
  • LAUDERBACK, Christopher; US
  • MONCRIEF, James, Scott; US
  • OBERLENDER, Rob; US
Mandataires
  • SCHULMAN, Robert, M. ; Hunton & Williams, LLP 1900 K Street, N.W. Suite 1200 Washington, DC 20006-1109, US
Données relatives à la priorité
60/473,92929.05.2003US
60/567,80105.05.2004US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) ABUSE RESISTANT AMPHETAMINE COMPOUNDS
(FR) COMPOSES D'AMPHETAMINE RESISTANT AUX ABUS
Abrégé
(EN)
The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
(FR)
L'invention concerne des composés, des compositions et des méthodes d'utilisation de ceux-ci. Ces composés et ces compositions comprennent une fraction chimique fixée de manière covalente à une amphétamine. Ces composés et ces compositions sont utiles pour réduire ou pour empêcher un abus ou une overdose d'amphétamine. Ces composés et ces compositions s'avèrent particulièrement utiles pour obtenir un traitement alternatif résistant aux abus pour certains troubles, notamment le trouble d'hyperactivité à déficience d'attention (ADHD), ADD, la narcolepsie et l'obésité. La biodisponibilité orale de l'amphétamine est maintenue à des doses thérapeutiquement utiles. A des doses supérieures, la biodisponibilité est sensiblement réduite, ce qui permet d'obtenir une méthode de réduction des risques d'abus oraux. En outre, l'invention concerne des composés et des compositions de l'invention permettant de diminuer la biodisponibilité de l'amphétamine par des voies parentérales, notamment une administration intraveineuse ou intranasale, ce qui permet de limiter encore le risque d'abus.
Également publié en tant que
EP2011194509
EP2011194519
IN2683/KOLNP/2005
NO20056211
NZ544162
PH12005502303
ZA200510383
Dernières données bibliographiques dont dispose le Bureau international